Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

GlaxoSmithKline PLC, consolidated statement of comprehensive income

US$ in millions, translated from GBP £

12 months ended:	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Profit for the year	4,781)	9,327)	7,715)	8,480)	2,852)
Exchange movements on overseas net assets and net investment hedges	(839)	(423)	(418)	(465)	256)
Reclassification of exchange on liquidation or disposal of overseas subsidiaries	(370)	—)	—)	(2)	(3)
Deferred tax on exchange movements	(3)	—)	—)	—)	—)
Fair value movements on available-for-sale investments	49)	608)	125)	(31)	145)
Deferred tax on fair value movements on available-for-sale investments	(132)	(48)	(16)	36)	(38)
Reclassification of fair value movements on available-for-sale investments	(262)	(63)	(31)	(45)	2)
Deferred tax reversed on reclassification of available-for-sale investments	98)	12)	16)	—)	(5)
Fair value movements on cash flow hedges	8)	(15)	(10)	—)	(12)
Deferred tax on fair value movements on cash flow hedges	(2)	2)	—)	—)	2)
Reclassification of cash flow hedges to income statement	(8)	3)	3)	2)	5)
Cash flow hedge reclassified to goodwill	—)	—)	—)	—)	9)
Share of other comprehensive income (expense) of associates and joint ventures	30)	25)	49)	(12)	—)
Exchange movements on overseas net assets of non-controlling interests	27)	(58)	—)	—)	—)
Remeasurement gains (losses) on defined benefit plans	(1,995)	1,404)	(1,270)	(1,506)	(2)
Deferred tax on actuarial movements in defined benefit plans	442)	(474)	359)	416)	2)
Other comprehensive income (expense) for the year	(2,956)	973)	(1,192)	(1,607)	359)
Comprehensive income for the year	1,826)	10,300)	6,523)	6,874)	3,211)
Comprehensive income for the year attributable to non-controlling interests	(154)	(260)	(242)	(238)	(368)
Comprehensive income for the year attributable to shareholders	1,672)	10,040)	6,281)	6,636)	2,843)

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Download chart

Comprehensive income item	Description	The company
Profit attributable to shareholders	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	GlaxoSmithKline PLC profit attributable to shareholders increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.
Comprehensive income for the year attributable to shareholders	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners.	GlaxoSmithKline PLC comprehensive income for the year attributable to shareholders increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.

GlaxoSmithKline PLC (NYSE:GSK)

Statement of Comprehensive Income